Labeling update reduces required post-infusion monitoring time for initial doses from 22 to 24 hours to 6 to 8 hours in patients with extensive-stage small cell lung cancer.

The FDA has expanded the indication for leniolisib to include younger pediatric patients with activated phosphoinositide 3-kinase delta syndrome (APDS).

The NDA is supported by phase 3 LATITUDE data demonstrating rapid and durable skin clearance in adults with moderate to severe plaque psoriasis.

Courts are limiting the "error in judgment" defense: why diagnostic missteps do not qualify as acceptable clinical decision-making under the law.

Coverage with at least one Tdap dose and at least one MenACWY dose decreased from 2024 to 2025; HPV did not increase for fourth consecutive year.

In the phase 3 LUNA trial, atogepant demonstrated a significant reduction in migraine days during the perimenstrual period compared with placebo.

First treatment approved for Alexander disease; Hyrnuo and Etcamah are approved for lung cancer and breast cancer, ...

Phase 3 Emerge trial results show a single 100µg dose of lysergide ODT produced rapid, statistically significant, and durable improvements in depression scores through 12 weeks.

HealthDay News — Semaglutide is associated with a significant reduction in airway exacerbations in patients with asthma or chronic obstructive pulmonary disease (COPD), according to a study presented ...

B-cell-depleting therapy linked to lower relapse incidence, greater T2 lesion volume reduction compared with oral platform therapies ...

Stage 1 to 3 CKM syndrome linked to significantly higher mean-mean, mean-maximum carotid intima-medial thickness.

HealthDay News — From 2019 to 2026, there was an increase in glucagon-like peptide-1 receptor agonist (GLP-1 RA) prescribing for children aged 8 to 11 years without diabetes but with obesity, ...